Clinical development failure
Drug candidates may not show sufficient efficacy or safety in preclinical or clinical testing.
- Scope
- PH-762, PH-894
- Materiality
- high
Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. is a U.S.-based clinical-stage biotechnology company focused on developing RNAi-based immuno-oncology therapies. Through its subsidiary MirImmune, LLC, the company advances INTASYL drug candidates such as PH-762 and PH-894 for potential use in cancer treatment.
17.81
17.81
| % | |
|---|---|
| RNAi therapeutic platform | 40% INTASYL-based RNA interference technology used to silence target genes in immune and cancer cells. |
| Clinical-stage oncology candidates | 35% Lead and pipeline drug candidates being developed for immuno-oncology applications. |
| Preclinical development services | 15% IND-enabling studies, translational research, and early-stage development work. |
| Intellectual property portfolio | 10% Patents and pending applications covering compounds, technologies, and geographic protection. |
Phio does not sell commercial products today; its primary counterparties are clinical collaborators, research vendors,...
- Clinical development partnersprimary
Research organizations and collaborators that support preclinical studies, assay work, and trial execution.
- Regulatory agenciesprimary
U.S. and other regulators that review IND submissions and clinical packages for PH-762 and PH-894.
- Future oncology prescribersemerging
Oncologists and cancer centers that would use approved therapies if the pipeline reaches commercialization.
- Capital providersprimary
Equity and debt investors that fund ongoing R&D and public-company operations.
Phio is headquartered in the United States and concentrates its development and patent activity there, while also...
- •Headquartered and primarily operated in the United States
- •U.S. is the main focus for clinical development and IND activity
- •Patent coverage extends to Canada, Europe, Japan, and other markets
- •International IP matters for partnering and future commercialization
- •No revenue geography disclosed because the company is pre-commercial
Phio’s strategy centers on advancing its lead immuno-oncology candidate PH-762 while continuing preclinical work on...
01
Advance PH-762 clinical developmentshort-term
The lead candidate is the main path to value creation and potential partnering.
02
Prepare PH-894 for IND submissionmedium-term
Broadens the pipeline and creates a second development asset.
03
Protect and rationalize IP portfoliomedium-term
Patent coverage supports exclusivity and future licensing leverage.
04
Secure development fundingshort-term
Clinical biotechnology requires ongoing external capital before product revenue exists.
Phio faces the typical risks of a pre-commercial biotech company: clinical and regulatory uncertainty, dependence on...
Nasdaq continued listing compliance
The company must maintain minimum bid price and equity requirements to remain listed.
- Scope
- Nasdaq Capital Market listing
- Materiality
- high
Financing dependence
Operations are funded primarily through external capital until any product revenue exists.
- Scope
- Equity, debt, strategic funding
- Materiality
- high
Supply and trade policy disruption
Research and development inputs may be delayed or become more expensive.
- Scope
- Preclinical and clinical development operations
- Materiality
- medium
Research and development accruals
Affects operating expense timing and liabilities
Stock-based compensation
Affects operating expenses and equity
Going-concern assessment
Affects disclosure and investor perception
Equity financing and reverse stock splits
Affects dilution and comparability
: 29.4.2026